{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-024795","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.924888+00:00","generated_at":"2026-06-19T01:28:45.981029+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cryoport reports Q4 2022 revenue $60.4M, full-year record $237.3M; guides FY2023 revenue $270-290M","bullets":["Full-year 2022 revenue $237.3M, up 7% YoY; commercial therapy revenue up 27% to $16.3M.","Net loss attributable to common stockholders $45.3M ($0.93/share) vs $283.7M ($6.18/share) in 2021.","Adjusted EBITDA $13.7M for 2022, down from $21.2M in 2021; Q4 adjusted EBITDA $0.7M.","Cash and short-term investments $523.3M at year-end; repurchased 1.6M shares for $37.9M in 2022.","FY2023 revenue guidance $270-290M (18% growth at midpoint); supporting 654 clinical trials and 10 commercial therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-024795","json":"https://secwatch.observer/filing/0001104659-23-024795.json","markdown":"https://secwatch.observer/filing/0001104659-23-024795.md","text":"https://secwatch.observer/filing/0001104659-23-024795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923024795/0001104659-23-024795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923024795/tm237715d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T01:28:45.981029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a029ad480e9688aa558b8109dc79751df8c8a8a","claim":"Cryoport, Inc. reported the fiscal year ended December 31, 2022 results: revenue $237.3 million. Guidance initiated.","evidence_excerpt":"Cryoport delivered a solid finish to 2022 with total revenue of $237.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923024795/0001104659-23-024795-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$237.3 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e34aeb0015f142a693e6ac7ace8676b6393cfd3e","claim":"Cryoport, Inc. reported the three months ended December 31, 2022 results: revenue $60.4 million. Guidance initiated.","evidence_excerpt":"Total revenue for the fourth quarter of 2022 was $60.4 million compared to $56.4 million for the fourth quarter of 2021, a year-over-year increase of 7%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923024795/0001104659-23-024795-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$60.4 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}